

# Voting Questions for the Committee

1) For the influenza A (H1N1) component of the 2023-2024 influenza virus vaccines in the U.S., does the committee recommend:

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus (Egg-based Vaccines)
- an A/Wisconsin/67/2019 (H1N1)pdm09-like virus (Cell- or Recombinant-based Vaccines)

2) For the influenza A (H3N2) component of the 2023-2024 influenza virus vaccine in the U.S., does the committee recommend:

- an A/Darwin/9/2021 (H3N2)-like virus (Egg-based Vaccines)
- an A/Darwin/6/2021 (H3N2)-like virus (Cell- or Recombinant-based Vaccines)

3) For the influenza B component of the 2023-2024 trivalent and quadrivalent influenza virus vaccines in the U.S., does the committee recommend inclusion of a B/Austria/1359417/2021-like virus (B/Victoria lineage)

4) For quadrivalent 2023-2024 influenza vaccines in the U.S., does the committee recommend inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2<sup>nd</sup> influenza B strain in the vaccine